ImmunityBio - About the company
ImmunityBio is a public company based in El Segundo (United States), founded in 2014. It operates as a Developer of peptide-based vaccines for immunotherapy. ImmunityBio has raised $169M in funding. The company has 3285 active competitors, including 1127 funded and 781 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of peptide-based vaccines for immunotherapy. The company's product includes N-803 that is an agonist of IL-15 used to modulate the activity of NK (Natural Killer)-mediated tumor cell killing. The company is developing next-generation cytokine antibodies, fusion proteins, and monoclonal antibodies.
- Website
- immunitybio.com
- Social
- Email ID
- *****@immunitybio.com
- Registered Address
- Culver City, California
Key Metrics
Founded Year
2014
Location
El Segundo, United States
Stage
Public
Total Funding
$169M in 9 rounds
Latest Funding Round
Investors
Ranked
47th among 3285 active competitors
Annual Revenue
$100M - $500M as on Dec 31, 2025
Employee Count
656 as on Jun 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with ImmunityBio
ImmunityBio is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Nantkwest, Inc. CIN: 431979754 , United States, Active | Dec 31, 1999 | $0 - $1M (As on Dec 31, 2020) | 678 (As on Dec 31, 2024) | - |
Immunitybio, Inc. CIN: 6387895 , United States, Active | Jan 27, 2022 | - | - | - |
IMMUNITYBIO, INC. CIN: 1326110 , United States, Active | Mar 11, 2014 | $100M - $500M (As on Dec 31, 2025) | 725 (As on Dec 31, 2022) | - |
ImmunityBio's IPO details
ImmunityBio got listed on Aug 31, 2015.
Click here to take a look at ImmunityBio's IPO in detail
Sign up to download ImmunityBio's company profile
ImmunityBio's funding and investors
ImmunityBio has raised a total funding of $169M over 9 rounds. Its first funding round was on Sep 10, 2015. Its latest funding round was a Post IPO round on Jan 11, 2024 for $*****. 1 investor participated in its latest round. ImmunityBio has 3 institutional investors.
Here is the list of recent funding rounds of ImmunityBio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 11, 2024 | 3333645 | Post IPO | 9299246 | 6495929 | 4855004 | 8684679 |
Sep 22, 2023 | 9098280 | Post IPO | 8125309 | 6785043 | 9318458 | 2793370 |
Dec 12, 2022 | 1340531 | Post IPO | 6114879 | 8279161 | 1615218 |
Access funding benchmarks and valuations. Sign up today!View details of ImmunityBio's funding rounds and investors
ImmunityBio's founders and board of directors
Founder? Claim ProfileImmunityBio's employee count trend
ImmunityBio has 656 employees as of Jun 26. Here is ImmunityBio's employee count trend over the years:
Uncover ImmunityBio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ImmunityBio's Competitors and alternates
Top competitors of ImmunityBio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ImmunityBio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
4th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
10th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
47th |  ImmunityBio 2014, El Segundo (United States), Public | Developer of peptide-based vaccines for immunotherapy | $169M | 67/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ImmunityBio's competitors? Click here to see the top ones
ImmunityBio's Investments and acquisitions
ImmunityBio has made no investments or acquisitions yet.
Reports related to ImmunityBio
Here is the latest report on ImmunityBio's geography:
News related to ImmunityBio
Filter this listMedia has covered ImmunityBio for a total of 57 events in the last 1 year, 19 of them have been about company updates and 3 about partnerships.
•
ImmunityBio's Anktiva Application for Expanded Cancer Drug Use Accepted for FDA ReviewLos Angeles Business Journal•Jun 08, 2026•ImmunityBio
•
•
•
•
•
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR Newswire•May 08, 2026•ImmunityBio, ClaimsFiler, Berger Montague, Rosenlegal and 1 other
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ImmunityBio
Explore our recently published companies
- Robbins-Aviation - Scottsbluff based, 2017 founded, Unfunded company
- Asetaviation - Unfunded company
- Dreamsaviationacademy - Unfunded company
- Dronshop - Unfunded company
- Aam Link - Unfunded company
- Grandlajja - India based, 2020 founded, Unfunded company
